Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct

Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct

The inhibition of renal SGLT2 glucose reabsorption has proven its therapeutic efficacy in chronic kidney disease. SGLT2 inhibitors (SGLTi) have been intensively studied in rodent models to identify the mechanisms of SGLT2i-mediated nephroprotection. So far, the overwhelming effects from clinical tri...

Full description

Bibliographic Details
Main Authors: Frederick Sinha, Anna Federlein, Annika Biesold, Magdalena Schwarzfischer, Katharina Krieger, Frank Schweda, Philipp Tauber
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Pharmacology
Subjects:
SGLT2 inhibition
empagliflozin
kidney weight
hypertrophy
HIF1α
pH
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1118358/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1118358/full

Similar Items